GOSS Gossamer Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1728117 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-58.0%
TTM net income YoY-71.6%
TTM EPS YoY-221.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-361.9%
Net margin-344.8%
FCF margin-383.7%
EBITDA margin-361.1%
Returns
ROE-783.4%
ROA-45.2%
ROIC (approx.)—
Asset turnover0.13x
Leverage & solvency
Liabilities / assets119.1%
Debt / equity—
Current ratio4.40x
Interest coverage-13.28x
Cash quality & payout
Operating cash flow / net income1.11x
Accruals ratio5.1%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $48.47M | $114.70M | $0 | $0 | — |
| R&D expense | $174.09M | $138.49M | $135.30M | $170.92M | $170.27M |
| SG&A expense | $37.63M | $36.13M | $38.45M | $47.61M | $45.78M |
| Operating income | -$170.73M | -$59.92M | -$183.76M | -$218.59M | -$216.12M |
| Interest expense | $10.99M | $11.52M | $13.51M | $13.88M | $19.44M |
| Pretax income | -$170.46M | -$55.63M | -$179.82M | -$229.38M | -$234.00M |
| Income tax | -$88,000 | $893,000 | $0 | $0 | — |
| Net income | -$170.37M | -$56.53M | -$179.82M | -$229.38M | -$234.00M |
| EBITDA | -$170.70M | -$59.09M | -$182.15M | -$216.76M | -$214.38M |
| EPS (basic) | -0.75 | -0.25 | -1.18 | -2.71 | -3.13 |
| EPS (diluted) | -0.75 | -0.25 | -1.18 | -2.71 | -3.13 |
| Weighted avg. shares (diluted) | 228.52M | 226.23M | 152.62M | 84.57M | 74.84M |
| Balance sheet | |||||
| Cash & equivalents | $37.73M | $46.07M | $32.11M | $111.97M | $183.47M |
| Short-term investments | $99.20M | $248.44M | $264.32M | $143.71M | $141.81M |
| Receivables | $12.23M | $5.34M | $0 | — | — |
| Current assets | $167.64M | $309.89M | $306.52M | $261.88M | $331.78M |
| PP&E, net | $64,000 | $10,000 | $1.65M | $3.98M | $5.32M |
| Total assets | $172.25M | $315.29M | $311.92M | $272.45M | $343.66M |
| Current liabilities | $63.44M | $45.01M | $51.60M | $49.23M | $39.86M |
| Short-term debt | — | $0 | $11.61M | $11.61M | $0 |
| Long-term debt | — | $0 | $814,000 | $11.99M | $29.08M |
| Total debt | — | $0 | $12.43M | $23.60M | $29.08M |
| Total liabilities | $295.01M | $285.80M | $249.15M | $260.37M | $222.19M |
| Shareholders' equity | -$122.76M | $29.49M | $62.77M | $12.08M | $121.46M |
| Net debt | — | -$46.07M | -$19.68M | -$88.37M | -$154.39M |
| Shares outstanding | 2.92M | 226.60M | 225.41M | 94.42M | 75.75M |
| Cash flow statement | |||||
| Operating cash flow | -$171.27M | -$3.47M | -$159.16M | -$187.03M | -$188.89M |
| Capital expenditure | $79,000 | $0 | $0 | $410,000 | $1.55M |
| Free cash flow | -$171.34M | -$3.47M | -$159.16M | -$187.44M | -$190.44M |
| Investing cash flow | $156.36M | $29.02M | -$110.97M | -$1.03M | -$117.43M |
| Financing cash flow | $6.42M | -$11.49M | $190.15M | $117.09M | $3.33M |
| Depreciation & amortization | $24,000 | $833,000 | $1.61M | $1.83M | $1.74M |
| Stock-based compensation | $10.55M | $20.62M | $28.52M | $42.55M | $32.01M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.